Dimensional Fund Advisors
BCRX icon

Dimensional Fund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dimensional Fund Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2M Buy
2,718,781
+28,130
+1% +$254K ﹤0.01% 1903
2026
Q1 		$25.6M Buy
2,690,651
+1,461,799
+119% +$11.4M 0.01% 1854
2025
Q4 		$9.59M Buy
+1,228,852
New +$8.88M ﹤0.01% 2297
2014
Q3 		– Sell
-3,679
Closed -$47K – 3546
2014
Q2 		$47K Buy
3,679
+3,300
+871% +$32.1K ﹤0.01% 3439
2014
Q1 		$4K Hold
379
– – ﹤0.01% 3577
2013
Q4 		$3K Hold
379
– – ﹤0.01% 3524
2013
Q3 		$3K Sell
379
-44,626
-99% -$226K ﹤0.01% 3556
2013
Q2 		$70K Buy
+45,005
New +$77.6K ﹤0.01% 3413

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Dimensional Fund Advisors's BCRX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 1% in Q2 2026, buying an estimated $254K and bringing the position to 2,718,781 shares worth $27.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Dimensional Fund Advisors first reported a position in BCRX in Q2 2013 and has held it in 8 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Dimensional Fund Advisors held 2,718,781 shares of BioCryst Pharmaceuticals worth $27.2M as of Q2 2026.
  • Dimensional Fund Advisors bought 28,130 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $254K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1903 holding.
  • Dimensional Fund Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.